Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation

Terzic, Julie; Seipel, Amanda; Dubuisson, Jean; Tille, Jean-Christophe; Tsantoulis, Petros; Addeo, Alfredo; Labidi-Galy, Sana Intidhar

doi:10.1016/j.gore.2020.100600

Scientific article

Case report

English

Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation

ContributorsTerzic, Julie; Seipel, Amanda; Dubuisson, Jean; Tille, Jean-Christophe; Tsantoulis, Petros

; Addeo, Alfredo; Labidi-Galy, Sana Intidhar

Published inGynecologic Oncology Reports, vol. 33, 100600

Publication date2020

Abstract

•Metastatic CSMD3 mutated HGSOC showed objective and sustained response to pembrolizumab.•The tumor was massively infiltrated by CD8+ T cells while PD-L1 TPS was at 10%.•CSMD3 mutated HGSOC showed up-regulation of CCL5 and CXCL9.

Affiliation entities

Research groups

Métastases du foie (657)

Citation (ISO format)

TERZIC, Julie et al. Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation. In: Gynecologic Oncology Reports, 2020, vol. 33, p. 100600. doi: 10.1016/j.gore.2020.100600

Article (Published version)

CC BY

Identifiers

PID : unige:146865
DOI : 10.1016/j.gore.2020.100600
PMID : 32613071

Journal ISSN2352-5789

291views

234downloads

Creation22/12/2020 09:17:00

First validation22/12/2020 09:17:00

Update15/03/2023 23:46:20

Status update15/03/2023 23:46:19

Last indexation31/10/2024 20:53:03

Archive ouverte UNIGE

Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation

•Metastatic CSMD3 mutated HGSOC showed objective and sustained response to pembrolizumab.•The tumor was massively infiltrated by CD8+ T cells while PD-L1 TPS was at 10%.•CSMD3 mutated HGSOC showed up-regulation of CCL5 and CXCL9.

Technical informations